TD Cowen Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $220.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lifted by research analysts at TD Cowen from $200.00 to $220.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target would indicate a potential upside of 31.98% from the company’s previous close.

Several other equities analysts also recently weighed in on the stock. Guggenheim lifted their price target on shares of Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Cantor Fitzgerald upped their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Morgan Stanley upped their target price on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average price target of $199.14.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX traded down $18.81 during mid-day trading on Friday, reaching $166.69. 2,511,969 shares of the company traded hands, compared to its average volume of 1,190,151. The company’s 50 day moving average price is $167.61 and its 200-day moving average price is $146.25. The firm has a market cap of $16.76 billion, a PE ratio of 25.65, a PEG ratio of 0.76 and a beta of 0.39. Neurocrine Biosciences has a 52 week low of $122.14 and a 52 week high of $186.12.

Insider Activity

In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total value of $2,364,750.00. Following the sale, the director owned 34,480 shares in the company, valued at $5,435,772. The trade was a 30.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the transaction, the insider directly owned 22,374 shares of the company’s stock, valued at $3,495,266.28. This trade represents a 62.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 395,422 shares of company stock valued at $62,448,693 in the last quarter. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Several large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. boosted its stake in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. DJE Kapital AG bought a new stake in Neurocrine Biosciences in the 4th quarter worth approximately $28,000. Basecamp Wealth Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 582.9% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares in the last quarter. Cassaday & Co Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter valued at approximately $33,000. Finally, Meeder Asset Management Inc. boosted its position in shares of Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after acquiring an additional 202 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported second-quarter revenue of $959 million, up 39% year over year and above analyst estimates of approximately $891 million. Adjusted earnings of $2.85 per share also exceeded consensus estimates. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA net product sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine raised its 2026 INGREZZA sales outlook to $2.825 billion–$2.875 billion. Neurocrine Biosciences Q2 Revenue Rises 39%
• Positive Sentiment: Several analysts raised their price targets after the report, including Stifel, Guggenheim, Needham, Cantor Fitzgerald and Piper Sandler. Targets generally remain above the current trading level, reflecting continued confidence in Neurocrine’s commercial portfolio and pipeline.
• Neutral Sentiment: The Soleno Therapeutics acquisition was completed in May, expanding Neurocrine’s portfolio with VYKAT XR. However, the product contributed only part-quarter sales, leaving investors focused on how quickly the acquisition can add meaningful growth.
• Negative Sentiment: Despite beating quarterly estimates, management did not deliver the broad-based guidance increase or major upside surprise that traders were seeking. The earnings update was therefore viewed as solid but insufficient to support higher expectations, contributing to the selloff.
• Negative Sentiment: Insider trading data shows substantial selling and no open-market purchases by insiders over the past six months. Director Leslie Norwalk’s latest sale involved 1,250 shares and was executed under a pre-arranged Rule 10b5-1 plan, making it a secondary bearish signal rather than clear evidence of a change in business fundamentals. SEC Insider Filing

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.